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ABSTRACT 
Alzheimer’s disease (AD) is one of the most common cause of dementia in older adults and an important public health problem. The purpose of 
this review article is to provide a brief introduction to A D and the related concept of mild cognitive impairment (M C I) and may throw light on 
the prevalence, causes, treatment, diagnosis and prevention. Vast knowledge regarding disease and disorders will help people take precautions 
for not getting effected by it. This will help reduce the number of Alzheimer’s disease. Since the exact curative treatment h as not been 
established for AD. AD is a complex disorder with environmental and genetic components. There are two major types of Alzheimer ’s disease, 
early on set and the more common late onset. The genetics of early-onset Alzheimer’s disease are largely understood with variants in three 
different genes leading to AD disease. In contrast, with several common alleles associated with late-onset Alzheimer’s disease, including APOE, 
have been identified using association studies, the genetics of late-onset Alzheimer’s disease are not fully understood. Continuing efforts are 
still required. This includes development of medicines that would slow progression, halt, or prevent AD and other dementias from occurring.  
Studies are currently underway to identify biomarkers for diagnosis and new therapeutical agents to prevent or slow down disease 
progression. 
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INTRODUCTION 
Alzheimer’s disease (AD) is the most common form of 
dementia, a fatal neurodegenerative disease where patients 
suffer from severe cognitive impairments, loss of memory, 
and the inability to function in later stages.1 Alzheimer’s 
disease (AD) is characterized by decreased cognition. 2 AD 
should be differentiated from normal age-related decline in 
cognitive function, which is more gradual and associated 
with less disability. AD usually starts with mild symptoms 
and ends with severe brain damage. People with dementia 
lose their abilities at different rate.3 
ALZHEIMER’S DISEASE  
History 
 Alois Alzheimer and Auguste D the German psychiatrist and 
neuropathologist Dr. Alois Alzheimer is credited with 
describing for the first time a dementing condition which 
later became known as AD. In his landmark 1906 conference 
lecture and a subsequent 1907 article, Alzheimer described 
the case of Auguste D, a 51-year-old woman with a ‘ peculiar 
disease of the cerebral cortex,’ who had presented with 
progressive memory and language impairment, 
disorientation, behavioural symptoms (hallucinations, 
delusions, paranoia),and psycho social impairment. 5, 6 
Remarkably, many of the clinical observations and 
pathological findings that Alzheimer described more than a 
century ago continue to remain central to our understanding 
of AD today.7 
 
Fig 1: Showing difference between healthy brain and AD 
brain.4 
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Epidemiology 
Although AD was long believed to be a rare disease, 
awareness of AD prevalence was highlighted in the late 
1960s and 1970s by blessed and colleagues and Katzman. 
Present epidemiological data suggest that dementia, defined 
as the clinical state of acquired cognitive loss in multiple 
domains, affects about 5–7% of individuals over age 65 yr .8 
Alzheimer’s disease (AD) has affected about 13% of the 
world’s population over the age of 60” (World Alzheimer 
Report, 2013, p. 1).  Between 2010 and 2050, the number is 
projected to increase from 101 million to 277 million 
worldwide (World Alzheimer Report, 2013); yet no current 
cure has yet been found for the disease (Parra-Dames et al., 
2014).9 The world’s population is rapidly aging, and the 
number of people with dementia is expected to grow from 
35 million today to 65 million by the year 2030.10 
Dementia 
The team “Dementia” is associated with memory loss and 
difficulties with thinking, problem solving or language.  It is 
the clinical condition which involves the deterioration of 
intellectual functions in an individual.11 various cognitive 
abilities can be impaired with dementia, including memory, 
language, reasoning, decision making, visuospatial function, 
attention, and orientation. Most individuals with dementia, 
cognitive impairments are often accompanied by changes in 
personality, emotional regulation, and social behaviours. The 
cognitive and behavioural changes that occur with dementia 
interfere with work, social activities, and relationships and 
impair a person’s ability to perform routine daily activities. 
12, 13 
Mild cognitive impairment  
The MCI Concept MCI is a syndrome characterized by 
memory and/ or other cognitive impairments that exceed 
the decline in cognition associated with the normal aging 
process. MCI is often regarded as a precursor to dementia or 
a transitional state between healthy cognitive aging and 
dementia (Fig. 2).14 
 
Fig 2: Progressive development of Alzheimer’s disease 
(AD). 
The relationship among pre-clinical, mild cognitive impairment 
(MIC) and Dementia stages of AD (dashed line) are shown relative to 
normal Cognitive aging (solid line). 
PATHOLOGY 
 The disease is characterized by oxidative stress, 
mitochondrial impairment, neuro-inflammation, synaptic 
dysfunction, and blood-brain barrier disruption, which may 
be caused in part by abnormal extracellular accumulation of 
amyloid-β peptide part by an abnormal extracellular 
accumulation of amyloid-β peptide (Aβ) in amyloid plaques 
and tau protein aggregation in intracellular neuro-fibrillary 
tangles (NFTs), which are the hallmarks of Alzheimer’s 
disease, causing synaptic and neuronal loss and enhancing 
cognitive dysfunction .15 
ETIOLOGY 
 In the past decade, tremendous strides have been made in 
determining the multifactorial aetiology of AD; Individuals 
with Down syndrome (trisomy 21) almost universally 
develop the neuropathology symptoms of AD after age 40 
years. 
Three genes have been found to be associated with the 
development of the early-onset familial form of AD, and one 
gene is considered as a risk factor most commonly in late-
onset form of AD. 16 The 4 genetic loci already known as 
contributing to AD do not appear to account for all of the 
genetic risk of the disease.  Chromosome 12 is recently 
suspected of having a susceptibility gene for AD. 17 
Mutations within the gene on chromosome 21, which 
encodes for myeloid precursor protein (APP), the precursor 
of myeloid beta (AP) peptides, are associated with about 2% 
to 3% of all cases associated with the early-onset familial 
form of AD. The presenilin 1 (PSI) gene located on 
chromosome 14 and the presenilin 2 (PS2) gene located on 
chromosome 1 are linked to 70% to 80% and 20% to 25% of 
the early-onset familial form of AD, respectively .18 The 
commonality between these 3 genes (ie, APP, PSI, continues 
to age, and PS2) is that they are increasing; alter APP 
processing, which leads to increased production of AP 
prevalence. According to the "amyloid cascade hypo- thesis," 
AP deposition is the initial critical event in the etiology and 
pathogenesis of AD; all other features of the disease follow 
(eg, neurofibrillary tangles, synapse and cell loss, dementia) 
.19, 20 Apo lipoprotein E has 3 different forms: E2, E3, and E4. 
It is a serum lipoprotein involved in cholesterol metabolism 
that is encoded by a gene (APOE) on chromosome 19. This is 
the only gene known to be associated with the more 
common late- onset forms of AD (familial and sporadic), 
accounting for 50% of the risk of AD. It is the inheritance of 
the E4 allele that confers the risk. Individuals   with 
homozygous form of E4 allele (E4/E4) are more likely to 
develop and have an earlier age of onset of AD than are those 
individuals with other genotypes of individuals with APOE 
alleles. The carriers of the E4 allele, however, show no 
cognitive impairment, % where as people without the E4 
allele can develop AD. 21 
Current etiological hypothesis of AD  
The neuropathological features of both forms of AD are 
characterized by abnormal extracellular accumulation of 
myeloid-β peptide (Aβ) in Amyloid plaques and tau protein 
aggregation in intracellular neurofibrillary tangles (NFTs). 22  
The Amyloid Hypothesis  
The main hypothesis of AD pathogenesis is the Amyloid 
cascade hypothesis, positioning amyloid aggregation as the 
mechanistic initiation event, where different stages of 
abnormal aggregates, from soluble oligomers to insoluble 
fibers or plaques, cause impaired synaptic function and 
neuronal damage that results into chronic neuro-
degeneration characterized by cognitive impairment and 
ultimately dementia .23 In this hypothesis, the accumulation 
of Aβ plaques acts as an enhancer in the pathological 
cascade, including neurite damage and neuro fibrillary 
tangle (NFT) formation via tau protein, which may results to 
neuronal dysfunction and cell death in AD. Genetic, 
biochemical, and pathological evidence support the amyloid 
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cascade hypothesis, which postulates that the accumulation 
and aggregation of Aβ plaques is the main cause of AD.24 
The Tau Hypothesis  
Tau proteins are mainly found in neurons and belong to the 
family of microtubule-associated protein (MAP); they 
develop long processes such as axons and dendrites for 
neuronal transmission. In the adult brain six tau protein iso-
forms derived by alternative splicing of gene have been 
identified; they are located on the long arm of chromosome 
17.Tau protein deposition in an insoluble aggregates results 
in a loss of tau function, leading to microtubule instability 
and promoting neurodegeneration. Intact microtubules are 
required for axonal transport and normal neuronal function; 
it has long been recognized that microtubule destabilization 
causes AD. 25  
The Cholinergic Hypothesis  
For many years, the cholinergic hypothesis has been the 
centre of study dementias and other neurodegenerative 
diseases. Acetylcholine is a neurotransmitter that is 
responsible for the conduction of electrical impulses from 
one nerve cell to another. 26 It has been proposed that the 
AChE produces non-cholinergic functions such as formation 
of NFTs and as Aβ deposition in the brain of AD patients. 27 
 The Mitochondrial Cascade Hypothesis 
 The mitochondrial cascade hypothesis has been associated 
with mitochondrial DNA (mtDNA) mutations, oxidative 
stress, and the presence of Aβ in mitochondria, which plays 
an important part in AD pathogenesis, because this induces 
mitochondrial dysfunction and neuronal apoptosis .28 The 
(mtDNA) mutations include CD2-associated protein, which 
induces mitochondrial fission and transport damage along 
axons due to dynamic actin remodelling. 29 APP could be 
used to regulates the mitochondrial Aβ levels, which may be 
targeted to the outer mitochondrial membrane and interfere 
with protein import. 30 
The Metabolic Hypothesis  
The metabolic hypothesis states that the disease is caused by 
some changes in metabolic processes such as obesity, 
diabetes, hypercholesterolemia, and others. Recent research 
suggests that there are strong relationships between AD and 
type 2 diabetes mellitus (T2DM). 31 The pathogenetic 
mechanisms through which T2DM causes cognitive 
impairment are not clearly established. The proposed 
scenarios connecting diabetes and dementia are numerous; 
they include vascular lesions, inflammation, oxidative stress, 
elevated glycolysis end products, insulin resistance, 
abnormal insulin receptor signalling, insulin degradation, 
and insulin’s relationship with Aβ-deposits. 32 Many 
researches support the hypothesis that AD responds to 
pathogenesis based on neuronal energy alterations, which 
are caused by insufficiencies in the glucose function. 
Metabolic abnormalities are mainly associated with brain 
insulin growth factor, which regulates energy production 
and insulin resistance.33 
The Vascular Hypothesis 
Vascular hypothesis basic principle is characterized by the 
reduction of cerebral blood flow. This hypothesis suggests 
that the neurodegenerative process is initiated by chronic 
cerebral hypo perfusion caused by aging, oxidative stress, 
and vascular conditions such as hypertension, 
atherosclerosis, and hyper cholesterolemia. 34 Hypo 
perfusion and hypoxia are one of the problems, but the 
breakdown of the blood-brain barrier also results in 
accumulation of neurotoxic serum proteins in the brain, 
inflammation, as well as vascular and synaptic dysfunction, 
which leads to defects in Aβ and Tau metabolism and 
clearance, which in turn cause vascular problems. 35   BBB 
dysfunction mediates the indirect neurotoxic effects of 
chronic hypoper fusion by promoting oxidative stress, 
inflammation and impaired glucose transport across the 
blood-brain barrier, and their permeability. 36  
CAUSES OF ALZHEIMER’S DISEASE  
The main cause for this disease is still not known, with age 
as the greatest risk factor. 37  
Genetic Mutations  
Changes in DNA have been associated with the development 
of neuro-degeneration; such changes may be controlled by 
epigenetic factors and also by hereditary changes, 
representing the familial form or “sporadic” mutations. 
Changes in mitochondrial pathways, protein degradation, 
free radical and oxidative stress control, and immune system 
functions may be induced by Genetic mutation. These 
genetic mutations affect cell function, allowing apoptosis and 
inducing neuro-degeneration. 38, 39  
 
 
 
Fig 3: Pathway to neurodegeneration in AD .40 
 Lou Diana et al                                                                                                      Journal of Drug Delivery & Therapeutics. 2019; 9(3):626-633 
ISSN: 2250-1177                                                                                    [629]                                                                                    CODEN (USA): JDDTAO 
Protein misfolding 
 Neurodegenerative diseases is associated with protein 
misfolding, a process which is related with genetic mutations 
or triggered by external factors that induces incorrect 
structural protein formation and function. It subsequently 
leads to their aggregation in oligomer form and in some 
cases as plates, stored intra cellularly, extracellular 
(Alzheimer’s disease). 41 
Protein Degradation  
Pathways Intracellular misfolded proteins maybe regulated 
by a degradation system called the polyubiquitination-
proteasome system. This system will select misfolded 
protein and forms an ubiquitin polymer with the protein, by 
ubiquitin ligase enzyme. The ubiquitinated protein is 
transported to the proteasome and degraded into small 
fragments, however, when these degradation pathways fail 
in the degradation of misfolded proteins, cell damage can be 
induced by oxidative stress and generation of toxic 
molecules. 42 
 Mitochondrial Dysfunction 
 The mitochondrion is an organelle, responsible for 
providing energy (ATP) to the cell, through the electron 
transport chain. Reactive oxygen species can induce 
oxidative stress by two pathways of damage: the electron 
transport chain and mtDNA. Those changes induce 
mitochondria dysfunctions, membrane lipid peroxidation, 
and decreased ATP calcium homeostasis compromise and 
mitochondrial permeability.  
This dysregulation also induces the intrinsic mitochondrial 
apoptotic pathways through the separation of the anti-
apoptotic protein Bax/Bcl2 complex, allowing the Baxprotein 
to carry out an interaction with a voltage-dependent channel 
for opening and permeability for calcium transition, 
processes which induce mitochondrial fragmentation. 
Eventually, cytochrome C is released from the mitochondria, 
and caspase 9 is activated; this in turn activates caspase 3. 
The activation of the caspases triggers programmed cell 
death. Another result which is related to mitochondrial 
dysfunction has been associated with the increase in free 
radicals and oxidative stress, which induces neuro 
degeneration. 43 
Neuro-Inflammatory Processes  
The inflammatory process in the central nervous system 
includes the activation of astrocytes, T-cell infiltration, 
microglia cells, cytokine release, and major histo 
compatibility complex class II expression. The activation of 
the inflammatory process may be because of the 
extracellular aggregation of misfolded proteins, cellular 
debris as a product of neurodegeneration, oxidative stress, 
and other external agents.44 
Role of environment for AD  
Several studies state a role for environmental effects on AD 
development. Richard Mayeux and Yaakov Stern recent 
review summarized the role of diet, activities, or diseases 
that potentially play a role in the onset of Alzheimer disease. 
Diabetes, dyslipidemia hypertension, obesity and smoking, 
all have been found to increase risk as well as the history of 
brain trauma, cerebrovascular disease, and vasculopathies. 
Also A higher level of education is included, hence 
mediterranean diet were shown to decrease the risk of 
developing AD.45 
 
Table 1:  Factors that modify the risk of Alzheimer disease 
Antecedent Direction  Possible Mechanism 
Cardiovascular disease Increased   Parenchymal destruction 
 Strategic location 
 Increase alpha beta deposition 
Smoking  Increased  Cerebrovasular effect 
 Oxidative stress 
Hypertension Increased and decreased  Micro-vascular disease 
Type 2 diabetes Increased   Cerebrovascular effect 
 Insulin and alpha beta compete for clearance 
Obesity Increased   Increased risk of type 2 diabetic inflammatory 
Traumatic head injury Increased   Increase alpha beta and amyloid precursor protein desposition 
Education  Decreased   Provides cognitive reserve 
Leisure activity  Decreased  Improves lipid metabolism,mental stimulation 
Mediterranean diet Decreased   Antioxidant, anti-inflammatory  
Physical activity Decreased   Activates brain plasticity,promotes brain vascularisation 
Source; Epidemiology of Alzheimer  Disease Richard Mayeux and Yaakov Stern cold spring Harb Perspect Med 2012;2. 
RISK FACTORS 
Known risk factors for AD include age and genetic factor; 
other possible risk factors are level of education, female sex, 
history of head injury, exposure to heavy metals and toxins, 
positive family history, and trisomy. 46, 47 the 𝜀4 allele is the 
risk allele and is the most significant known genetic risk 
factor for LOAD. This allele was first identified as a genetic 
risk factor for LOAD in 1993 by Corder et al, The association 
for this allele has been replicated numerous times in various 
ethnic groups including Caucasians, Although AD risk is 
much higher in persons with one or more 𝜀4 alleles, 𝜀4 is not 
causative and some individuals homozygous for 𝜀4 never 
develop AD. 48 African Americans 49, 50 Hispanics and Asians 
51, 52   the 𝜀4 allele is the only widely accepted genetic risk 
factor for LOAD. 53 and increases risk with increasing 𝜀4 
dosage. In contrast to decreases AD risk Possible APOE 
genotypes, listed in order of AD risk, are Possible APOE 
genotypes. 54  
DIAGNOSING OF ALZHEIMER’S DISEASE  
An autopsy-based (post-mortem) pathological evaluation is 
a gold standard for AD diagnosis. The presence and 
distribution of amyloid plaques and NFT in the brain is used 
to establish the stage the disease and diagnosis of definitive 
AD stage the disease. 55 in clinical settings, the doctors can be 
able to diagnose this disease with the help of taking medical 
history and neurological examinations. The accuracy for 
these diagnoses would be about 70-90% right. Alzheimer’s 
disease is usually diagnosed when there are cognitive or 
behavioural (neuropsychiatric) symptoms. 56 
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Biomarkers 
 There are several biomarkers approach which can be used 
to study Alzheimer’s disease. Biomarkers are required to 
select patients during studies and also to identify high risk 
patients for early treatment as well as monitoring the 
patient’s disease progression or response to treatment. The 
biomarkers include: - Magnetic Resonance Imaging (MCI), 
Positron emission tomography, fluid biomarkers etc.   
Magnetic Resonance Imaging  
This involves the use of radio frequency waves and strong 
magnetic field, and measures the energy released by protons 
in various tissues and parts of the brain.  The study of the 
regional patterns of brain atrophy in patients can be 
achieved by this method. 
 Positron Emission Tomography  
It is a technique which uses nuclear imaging and it also helps 
to measure the regional brain metabolism. The earliest signs 
of Alzheimer’s disease can also be detected.  
Fluid Biomarkers  
It’s based on the blood plasma and the CSF. They are used 
for diagnosis purposes as well. 57 Several studies have been 
conducted using immunoassays to measure the levels of 
various proteins in the CSF, finding that patients with AD 
show decreased levels of the 42 amino acid isoform of the Ab 
(Ab-42) peptide and elevated levels of the phosphorylated 
tau (P-tau) peptide.58, 59 
Treatment 
Drug therapy for the AD is still in its infancy, till now there is 
no cure for AD, and drug therapy for the disease is still in its 
infancy. The approved medications for the treatment of 
probable AD is limited in controlling the symptoms of AD but 
do not slow down the progression or reverse the course of 
the disease. 60   FDA approved 5 drugs for treatment of AD 
symptoms. These approved drugs are able to treat 
symptoms of mild-to-moderate cases but do not slow down 
the progression of the disease. They work to either increase 
levels of acetylcholine, a protein important for memory and 
thinking, by inhibiting an enzyme responsible for its 
breakdown or by regulating levels of the brain protein 
glutamate, which accumulate in people with AD and kills 
brain cells. In a recent study, researchers found that one of 
these, Aricept, led to a 6-month delay in further symptoms. 
61 
Cholinesterase inhibitors  
Cholinesterase inhibitors are class of medicinal agent that 
block cholinesterase, which is an enzyme that breaks down 
the neurotransmitter acetylcholine. AD is linked with low 
levels of acetylcholine, hence inhibiting or blocking the 
breakdown of acetylcholine through cholinesterase 
inhibitors may help to improve brain function. 62 
Glutamatergic agents 
A glutamatergic NMDA receptor blocker, known as 
memantine is an effective agent used in treating severe AD. 
This drug was first approved in Germany since 1970’s, but 
clinical trial data to support its use have been limited.  
Therefore recent clinical trials data for investigating the 
safety and clinical efficacy of memantine show that it is 
effective for moderate to severe AD. The medication is still 
being studied and is approved in the United States and 
several European countries.  Current Pharmaceutical 
Products “Pipeline” for AD Treatment  
 
Table 2: New medicines in development for Alzheimer disease 
Drug Name Indication  Company  Development  
Status 
ABT-126 acetylcholinesterase inhibitors Alzheimer disease Abbott Phase 2 
ABT-126 Alzheimer disease Abbott Phase 2 
LY2886721 Alzheimer disease Eli Lilly and Company Phase 1 
AZD3480 Alzheimer disease Targacept InC. Phase 2 
AVP-923(dextromethorph an/quinidine) Alzheimer disease, mild 
cognitive impairment 
Avanir Pharmaceuticals Phase 2 
MABT5102A Alzheimer disease Genentech Phase 2 
AZD5213 Alzheimer disease AstraZeneca Phase 2 
Gantererumab Alzheimer disease Hoffmann-La Roche Phase 3 
AAB-003(PF-05236812) Alzheimer disease Pfizer Phase 1 
BMS-241027 Alzheimer disease Bristol-Myers Squibb Phase 1 
MABT5102A Alzheimer disease Genentech Phase 2 
BIIB037 Alzheimer disease Biogen Idec Phase  1 
GSK2647544 Alzheimer disease GlaxoSmithKline Phase  1 
 
The beneficial effects of nutraceuticals A study conducted by 
Trully in 2002 with 148 subjects with dementia and 45 
healthy controls found that the serum docosahexaenoic acid 
(DHA) of AD subjects were significantly decreased. 63 The 
DHA is the main omega 3 polyunsaturated fatty acid (O-3 
PUFA) amongst eicosapentaenoic acid (EPA). Evidences 
suggest that body low levels of O-3 PUFAs may be associated 
with the development of neurodegenerative diseases, 
including AD. Large scale intake of O-3 PUFAs can lower the 
risk of AD and slower cognitive decline related to age.  64 
PHYSICAL ACTIVITY AND AΒ- INDEPENDENT 
MECHANISMS  
Several studies have shown that physical activity can also 
improve cognitive function in AD and MCI patients through 
Aβ-independent mechanisms. It has been shown that 
physical activity increases neurotrophic factors such as 
BDNF levels in the brain and through their neuro-protective 
effects improve cognition in AD (Erickson et al., 2012). Also, 
regular physical activity acts as a pre-conditioner against 
oxidative stress and reactive oxygen species production 
(ROS).
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  Fig 4: Mechanisms of physical activity in prevention of Alzheimer’s disease risks. 65 
 
PSYCHIATRIC MANAGEMENT OF NON-COGNITIVE SYMPTOMS  
Early intervention is important since psychiatric symptoms can respond to treatment more readily than cognitive and 
functional deficits.66   
 Table below shows the behavioural clusters manifested in AD and relevant classes of medications for intervention.  
Table 3: Behavioural clusters Matched with potentially Relevant Classes of Medication 
Behaviour Agent 
Agitation/aggression Antipychotics, anticonvulsants, antidepressants, anxiolytics 
Anxiety Antidepressants, anxiolytics, anticonvulsants 
Apathy Antidepressants, stimulants 
Disturbed effect/mood Antidepressants, anticonvulsants 
Altered ideation/mood Antisepsychotics 
Vegetative Features Antidepressants, anxiolytics, stimulants. 
Source: American psychiatric association Practice guidelines for the treatment of Alzheimer Disease and Other dementias of 
Late Life 
 
CONCLUSION 
Early prevention in preclinical stages is the most effective 
way to protect brain and reduce risk of. It seems that 
physical activity especially aerobic exercise is one of these 
preventing factors. New funding models should be explored 
which can support core research facilities and non-tenured 
staff in academic institutions, such as the creation of 
endowments for facilities and pharmaceutical and biotech 
consortia. Innovation is needed to encourage diversity of 
approaches to fight AD. In 2012, dementia was declared a 
public health priority by the World Health Organization 
(WHO). The number of patients with Alzheimer disease will 
rise significantly Due to the ageing of the world population. If 
no treatment is available, this will result to a major health 
issue with enormous financial burdens to health care 
systems. 
CONFLICT OF INTERESTS  
The authors declare no conflict of interests. 
ACKNOWLEDGMENTS 
Authors are thankful to the management of the department 
of pharmacology, Karnataka college of Pharmacy, Bangalore, 
Karnataka, India for providing necessary materials, 
information and ideals regarding the study.   
REFERENCES 
1. Raymond C, Linda Z. Current neuroimaging techniques in 
Alzheimer's disease and applications in animal models.  Am J 
Nucl Med Mol Imaging .2012; 2(3):386-04. 
2.  Mark T, Perry G. Review Article Genetics of Alzheimer’s disease. 
Bio Med Research International.2013; 7(1):1-13. 
3.  Gross A, Jones R, Habtemariam D, Fong T, Tommet D, Quach L, 
Schmitt E, Yap L, Inouye SK. Delirium and Long-term Cognitive 
Trajectory Among Persons With Dementia. Arch Intern Med. 
2012; 172(17):1324-31. 
4. Sheldon F, Shaffer J, Petrella J, Choudhury K, Calhoun V, Coleman 
R, Doraiswamy P.  alzheimer’s Disease Neuroimaging Initiative. 
Predicting Cognitive Decline in Subjects at Risk for Alzheimer 
Disease by Using Combined Cerebrospinal Fluid, MR Imaging, 
and PET Biomarkers. Radiology. 2013; 266(2):583-91. 
5. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnridne. 
About a Peculiar Disease of the Cerebral Cortex. Allg Z Psychiatr. 
1907; 64: 146-48. 
6. Alzheimer A. About a peculiar disease of the cerebral cortex. 
Alzheimer Dis Assoc Disord. 1987; 1(3); 8. 
7.  Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer’s 
disease. Lancet .1997; 349(9064): 1546. 
Physical activity 
NEP, IDE APP, BACE1, 
PS1,αβ 
Reduced risk of 
AD 
 Lou Diana et al                                                                                                      Journal of Drug Delivery & Therapeutics. 2019; 9(3):626-633 
ISSN: 2250-1177                                                                                    [632]                                                                                    CODEN (USA): JDDTAO 
8. Alan   J. Lerner, Women and Alzheimer’s disease. The Journal of 
Clinical Endocrinology & Metabolism. 1999; 84(6); 1830-1834. 
9. Edith, Samuel. Recent Research and Updates on Alzheimer’s 
disease. Journal of Psychology and Behavioural Science.2014; 
2(2); 103-12. 
10. Korole v, Igor O. Alzheimer’s disease. A Clinical and Basic Science 
Review. Medical Student Research Journal; 2014; 04(9); 024-
033. 
11. Reshma H .Alzheimer's Disease- A Review, J. Pharm. Sci. & 
Res.2016; 8(11): 1292-94. 
12. Gilman S. Oxford American handbook of neurology. Oxford 
University Press: Oxford, UK; 
2010.ISBN 10: 0195369793 ISBN 13: 9780195369793. 
13. Hyman B , Jack C , Kawas C , McKhann G , Knopman D, Chertkow 
H. The diagnosis of dementia due to Alzheimer’s disease: 
recommendations from the National Institute on Aging-
Alzheimer’s Association workgroups on diagnostic guidelines for 
Alzheimer’s disease. Alzheimers Dement .2011; 7(3):26-39.  
14. Seeley W, Kim E , Rabinovici G D, Gorno-Tempini M L, Rascovsky 
K, Pagliaro TA. Distinct MRI atrophy patterns in autopsy-proven 
Alzheimer’s disease and front to temporal lobar 
degeneration.Am J Alzheimers Dis Other Dement .2007; 22:474-
88.  
15. Van Broeckhoven C, Van Cauwenberghe C, Sleegers K. The 
genetic landscape of Alzheimer disease. Clinical implications and 
perspectives. Genet Med. 2016; 18:421-30. 
16.  Filley C M. Alzheimer's disease in women. Am J Obstet Gynecol. 
1997; 176:1-7. 
17. Bass M P, Pericak-Vance MA, Yamaoka LH. Complete genomic 
screen in late-onset familial Alzheimer's disease: evidence for a 
new locus on chromosome 12. JAMA. 1997; 278:1237-41. 
18. Hardy J. The Alzheimer family of diseases: many etiologies, one 
pathogenesis Proc Natl Acad Sci USA. 1997; 94:2095-97. 
19. Singh V K. Neuroautoimmunity: pathogenic implications for 
Alzhei- mer's disease. Gerontology. 1997; 43:79-89. 
20. Singer S J, Delvji N N. Genetic clues to Alzheimer's disease. 
Science. 1996; 271:159-60. 
21. Lendon C, Goate A M, Ashall F. Exploring the etiology of 
Alzheimer disease using molecular genetics. JAM. 1997; 
277:825-31. 
22. Hasegawa M. Molecular Mechanisms in the Pathogenesis of 
Alzheimer’s disease and Tauopathies-Prion-Like Seeded 
Aggregation and Phosphorylation. Biomolecules. 2016; 6(2):24.  
23. Schöll M, Hansson O, Zetterberg H ,Blennow K, Mattsson N. 
Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol 
Sci. 2015; 36:297-09.  
24.  Barage S H, Sonawane, K D. Amyloid cascade hypothesis: 
Pathogenesis and therapeutic strategies in Alzheimer’s disease. 
Neuropeptides. 2015; 52:1-18. 
25. Khan A, Kalra J. Reducing AÎ² load and tau phosphorylation: 
Emerging perspective for treating Alzheimer’s disease. Eur J 
Pharmacol. 2015; 764:571-581. 
26. Singh B, Anand P. A review on cholinesterase inhibitors for 
Alzheimer’s disease. Arch Pharm Res. 2013; 36: 375-99. 
27.  Jellinger K A. Basic mechanisms of neurodegeneration: a critical 
update. J Cell Mol Med. 2010; 14:457-87. 
28. Saykin, Ramanan VK. Pathways to neurodegeneration: 
mechanistic insights from GWAS in Alzheimer´s disease, 
Parkinson´s disease, and related disorders. Am J Neurodegener 
Dis. 2013; 2:145-75. 
29.  Beal M F, Lin M T. Mitochondrial dysfunction and oxidative 
stress in neurodegenerative diseases. Nature. 2006; 443:787-95. 
30.  Harrison F E Walker J M. Shared Neurophatological 
Characteristics of Obesity, Type 2 Diabetes and Alzheimer´s 
Disease: Impacts on Cognitive Decline. Nutrients. 2015; 7: 7332-
57.  
31.  Mattson M P, Kapogiannis D. Disrupted energy metabolism and 
neuronal circuit dysfunction in cognitive impairment and 
Alzheimer’s disease. Lancet Neurol. 2011; 10: 187-98.  
32. Marschoff E R, Gonzalez S E Domínguez R O, Pagano M A, 
Repetto M G, et al. Alzheimer disease and cognitive impairment 
associated with diabetes mellitus type 2 associations and 
hypothesis. Neurología. 2014; 29:567-72. 
33.  Soiza R L, Kelleher R J. Evidence of endothelial dysfunction in 
the development of Alzheimer’s disease: Is Alzheimer’s a 
vascular disorder. Am J Cardiovasc Dis. 2013; 3:197-26.  
34.  Karran E, De Strooper B. The Cellular Phase of Alzheimer’s 
disease. Cell. 2016; 164:603-15.  
35.  Di Marco LY, , Evans PC, Marzo A ,Venneri A, Farkas E. 
Neurobiology of Disease Vacular dysfunction in the pathogenesis 
of Alzheimer´s disease – A review of endothelium mediated 
mechanisms and ensuing vicious circles. Neurobiol Dis. 2015; 
82:593-606.  
36. Janota C, Brito M A, Lemere CA. Dissecting the Contribution of 
Vascular Alterations and Aging to Alzheimer’s disease. Mol 
Neurobiol. 2016; 53: 3793-811. 
37. Busse A. Mild cognitive impairment long-term course of four 
clinical subtypes. Neurology.2006. 67(12):2176-85. 
38.  Tanzi R E, Bertram L. The genetic epidemiology of 
neurodegenerative disease. J Clin Invest. 2005; 115:1449-57.  
39.  Coppedè F, Migliore L. Genetics, environmental factors and the 
emerging role of epigenetics in neurodegenerative diseases. 
Mutat Res. 2009; 667: 82-97. 
40. Andrew J Saykin, Vijay K. Pathways to neurodegeneration: 
mechanistic insights from GWAS in Alzheimer’s disease, 
Parkinson’s disease, and related disorders. Am J Neurodegener 
Dis 2013; 2(3):145-75. 
41. Nestler EJ, Malenka RC, Hyman SE. Molecular 
Neuropharmacology: Neurodegeneration. China: McGraw-Hill. 
2009. 
42. Di Mauro S, Schon EA. Mitochondrial disorders in the nervous 
system`Annu Rev Neurosci. 2008; 31:91-123. 
43. Glass C K, Saijo K, Gage F H, Winner B, Marchetto MC. 
Mechanisms underlying inflammation in neurodegeneration. 
Cell. 2010; 140: 918-34. 
44. Richard Mayeux and Yaakov Stern .Epidemiology of Alzheimer 
Disease. Stern Cold Spring Harb Perspect Med 2012; 2(8):1-18. 
45. Lendon C L, Goate A M, Ashall F. Exploring the aetiology of 
Alzheimer disease using molecular genetics. JAM. 1997; 
277:825-31. 
46.  Gilnian S. Alzheimer's disease. Perspect Biol filed. 1997; 40:230-
45.  
47.  Knight J A. Reactive oxygen species and the neurodegenerative 
disorders. Am Clin Lab Sci. 1997; 27:11-25. 
48. Saunders AM, Strittmatter WJ. “Gene dose of apolipoprotein E 
type 4 allele and the risk of Alzheimer’s disease in late onset 
families,”Science.1993; 261(.5123):921– 23. 
49.  Hendrie HC, Hui S, Hall KS, Apolipoprotein E genotypes and 
Alzheimer’s disease in a community study of Bio Med Research 
International 9 elderly African Americans,”Annals of 
Neurology;1995;37(1):118–20. 
50.  Ottman GR, Stern Y.  “Apolipoprotein E and Alzheimer’s disease: 
ethnic variation in genotypic risks,”Annals of Neurology.1995; 
37(2):254–59.  
51. Noguchi S, Yamada N, K. Murakami. “Apolipoprotein E genotype 
and Alzheimer’s disease,” The Lancet; 1993; 342(8873):737–38. 
52.  Kawano M, Ueki A, Namba Y, Kawakami M, and Ikeda K. “A high 
frequency of apolipoprotein E4 isoprotein in Japanese patients 
with late-onset non familial Alzheimer’s disease, Neuroscience 
Letters. 1993; 163(2):166–68.  
53. Abraham, D. Harold, P. Holling worth. “Genome wide association 
study identifies variant sat CLU and PICALM associated with 
Alzheimer’s disease. Nature Genetics.2009; 41:1088–93.  
54. Corder EH, Risch NJ, Saunders AM. “Protective effect of apolipo-
protein E type 2 allele for late onset Alzheimer disease .Nature 
Genetics.1994; 7(2):180–84. 
55. Mc Khann. The diagnosis of dementia due to Alzheimer’s 
disease: Recommendations from the National Institute on Aging-
Alzheimer’s Association workgroups on diagnostic guidelines for 
Alzheimer's disease. Alzheimer's & dementia. 2011; 7(3): 263-
69. 
56. Braak H, Thal D R, Del Tredici K, Ghebremedhin E. Stages of the 
pathologic process in Alzheimer disease: age categories from 1 
to 100 years. J Neuropathol Exp Neurol 2011; 70:96-09.  
57. Guhne U, Busse A, Hensel A, Angermeyer MC, Riedel-Heller SG. 
Mild cognitive impairment: long-term course of four clinical 
subtypes. Neurology .2006; 67:217685.  
58.  Weigand S D, Shaw L M ,Vemuri P, Wiste H J, Trojanowski J Q, 
Weiner M W. MRI and CSF biomarkers in normal, MCI, and AD 
subjects: diagnostic discrimination and cognitive correlations. 
Neurology .2009; 73:287-93.  
59. Weiner M W, Beckett L A, Cairns N J, Green R C, Veitch D P, Aisen 
P S. The Alzheimer’s disease Neuroimaging Initiative: a review of 
papers published since its inception. Alzheimers Dement. 2012; 
8: S168. 09.172. 
 Lou Diana et al                                                                                                      Journal of Drug Delivery & Therapeutics. 2019; 9(3):626-633 
ISSN: 2250-1177                                                                                    [633]                                                                                    CODEN (USA): JDDTAO 
60.  Roche H M, Doyle R, Tully A M. Low serum cholesteryl ester-
docosahexaenoic acid levels in Alzheimer’s disease: a case–
control study. Br J Nutr. 2003; 89:483-89. 
61.  Morris M C, Bienias J L, Evans D A. Dietary intake of antioxidant 
nutrients and the risk of incidence Alzheimer disease in a 
biracial community study. JAMA. 2002; 287:3230-37.  
62.  Colacicco A M, Solfrizzi A, D’Introno A. Dietary intake of 
unsaturated fatty acids and age-related cognitive decline: A 8.5-
year follow-up of the Italian Longitudinal Study on Aging. 
Neurobiol Aging. 2006; 22(6):282-286. 
63. Phillips M A, Calder P C Childs C E. No Effect of Omega-3 Fatty 
Acid Supplementation on Cognition and Mood in Individuals 
with Cognitive Impairment and Probable Alzheimer's disease: A 
Randomised Controlled Trial. Int J Mol Sci. 2015; 16(10):24600-
13. 
64. Bullock R. Drug Treatments in Alzheimer Disease. Alzheimer’s 
disease International.  Fact sheet 8. Revised April 2000. Last 
accessed April 1, 2004. 
http://www.alz.co.uk/alzheimers/treatment.html   
65. Roecklein K A, Erickson K I, Miller D L. The aging hippocampus: 
interactions between exercise, depression, and BNDF. 
Neuroscientist. 2012; 18:82-97. 
66. Patrick D. McGorry, Eóin Killackey, Alison Yung. Early 
intervention in psychosis: concepts, evidence and future 
directions. World Psychiatry. 2008 Oct; 7(3):148–156. 
 
 
 
